||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Proteome Share Discussion Threads
Showing 173901 to 173920 of 173925 messages
20 Feb '17 - 16:58 - 68577 of 68579 12 0|
|From today's Guardian:
"The prospect of an effective treatment for Alzheimer’s has had knockbacks in the past year as a string of drugs designed to sweep away the amyloid plaques seen in the brains of patients have each been shown to make no difference to the rate of cognitive decline in trials. Between 2002 and 2012, 99.6% of drugs studies aimed at preventing, curing or improving Alzheimer’s symptoms were either halted or discontinued."|
|Capitulation .... at a price twice that of today's.|
|This new poster comes across as a complete KOCK!!!!
saul goodman 20 Feb '17 - 14:49 - 68576 of 68576 0 0 (Filtered) =====================================================================================|
Hmmm! Not sure about the reputational damage to Randox.|
|I note that the word "may" is used twice in the final sentence of the conclusion.|
|Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics.
Ian Pike Malcolm Ward
Proteome Sciences, London,UK
and Authors at :-
Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK.
Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
Neurodegenerative parkinsonian syndromes have significant clinical and pathological overlap, making early diagnosis difficult. Cerebrospinal fluid (CSF) biomarkers may aid the differentiation of these disorders, but other than α-synuclein and neurofilament light chain protein, which have limited diagnostic power, specific protein biomarkers remain elusive.
Using an unbiased proteomic approach, proteins were identified that were able to differentiate atypical parkinsonian syndrome patients from healthy controls. Our study indicates that markers that may reflect neuronal function and/or plasticity, such as the amyloid precursor protein, and inflammatory markers may hold future promise as candidate biomarkers in parkinsonism.
|Stocky......This is exactly the reason why you make things so difficult for yourself and the many others who are so reluctant to communicate with you. Read my post again......I asked for your opinion whether to buy now, or wait until later if you thought that the share price may be lower.Straight away you accuse me of "attacking" the stock and start banging on about how much that you think I am upset about losing money, even after having told you, now, at least 3 times in the recent past that I printed a 95pps profit on 350k PRM shares back in 2004.Now we know that the chances of that ever happening again are absolutely zero, but for alky and a few of the chaps who are looking to have a little flutter, and may well value your opinion, would you buy now or wait to see if the share price will go lower?|
|bodger, you are incredibly obsessive about attacking this stock for someone claiming not to have lost money on it
what a pair you and fgnoms are. He at least admits holding 1m shares and losing a fortune|
|Thermo Fisher Webinar March 16, 2017
Open 10 Doors at Once: Sample Multiplexing with 10-plex Tandem Mass Tags (TMT) Provides a New Perspective on any Biology.
The ability to perform accurate protein quantification at low levels lets scientists unravel the complexity of protein interactions, and track protein abundance changes in a wide variety of samples and applications.
The proteome is complex and dynamic and innovative tools are needed to study the complexities of biology. In fact, the full measure of proteome changes can rarely be encapsulated in a single time point representing a snapshot of the dynamics.
Sample multiplexing using Tandem Mass Tag (TMT) when combined with an appropriate Thermo Scientific Orbitrap HRAM MS enables scientists to ask real questions of their samples and obtain a meaningful description of how protein expression changes with disease, with the progression of time, and even within different parts of the cell. TMT workflows enable more than simple multiplexed quantitation; they open the door to defining whole new sets of questions.
In this webinar, case studies will be highlighted from the Gygi lab and ThermoFisher Center for Multiplexed Proteomics at HMS demonstrating the robustness of the technique, and more importantly, how to apply these workflows to a variety of analyses to answer a breadth of biological questions.
|You're asking an ex Meldex shareholder ("it was fraud" bawl bawl) for investment advice Badger? The guy is the worst sufferer of Murphy's Syndrome that I've ever known. Whatever he says do the opposite.|
|Having said all that stocky, are you saying that it would be better to buy shares now or wait until the price drops a bit?|
I think it's important to differentiate
'continued search for markers and drug testing' - PRM has been gradually moving away from internal and grand projects here
'continued search for markers and drug testing' - Externally, as in trying to make money off firms working on this, yes, very much so
'if continued, would appear to get them through (just) without another fundraising and I think it becomes another story once the company becomes self-sustaining financially'
I'm quite surprised to hear this from you, but yes, that is the strategy and I also agree it is not an unrealistic prospect
The less intelligent folk here will just blindly attack the company without actually stopping to think about things in the way you have!|
|Just to give everyone a laugh, I have to tell you that I have seriously considered taking a punt. Only 'fruit machine' money, but it may be worth a gamble if I'm prepared to risk losing my stake. The apparent acceleration in H2 revenues (pace badger/jam's(?) claim it was all currency related), if continued, would appear to get them through (just) without another fundraising and I think it becomes another story once the company becomes self-sustaining financially. I'm not sure about 'profitability in 2018' (I think there is still a lot of confusion between revenues and profit!), but just assured survival changes the ball game.
Alchemy's 'capitulation' was another contra-cyclical indicator! 8-)
Some years's ago, although not a holder, I attacked the business model of Regus, the serviced office provider since renamed IWG, and was sure it was going to go bust. To all intents and purposes it did, going down from £4 to around 3p with one large institutional holder capitulating and selling out at 1.8p, but remarkably - and after some 'interesting' shenanigans involving John Mouton's Better Capital group - it survived. Price today? 265p. Spotting spotty dog's is one thing. Spotting the moment they change their spots can bring rewards.|
|That's not "yes and no", it's "yes" isn't it, doc? We're saying exactly the same thing. Whilst the Holy Grail of a certain diagnosis and/or a blockbuster drug is some way off, the continued search for markers and drug trials mean that that side of PRM's business is secured and growing.|
"The continued search for markers and drug testing is presumably what Haigh's strategy is all about when he says he wants to make TMT and pharma services the 'core business' of PRM"
Yes and no.
Haigh's strategy is about things like
a) focusing on facilitating more growth of the TMT royalty stream ie. working with Thermo to broaden its use into the mainstream, via greater awareness of existing workflows and introduction of new chemistry types
b) selling PRM's contract service business to clients, to get more repeat business, larger contract sizes and work with new clients
PRM has in the past invested a lot in AD marker panels with KCL
Clearly some of a and b could relate to AD projects, just as much as anything else, but I'd separate what Haigh is trying to do from any of PRM's past AD efforts.
Whether there's anything still to be had from the AD panels or ongoing work, I don't know. I'd guess that they'll probably just be advanced slowly by grants etc. rather than be a focus of any of PRM's investment|
|Good luck alky. I see 90k has traded today. Hopefully you will be able to knock those out sometime soon in the mid 5's and make yourself a few bob.|
|Surely Al's post deserves to be included in JT's above list of amusing posts. There's been precious little humour or significant or informative posts included over recent times.|
|May I echo teh avatar 'saul goodman's' good wishes to teh avatar Alchemy in teh event that he chooses teh course of action currently under consideration.|
Well, good luck if you do, Al.|